Zaleplon

Randomly controlled study on insomnia treated with domestic zaleplon

国产扎来普隆治疗失眠症随机对照研究

Experimental study on general pharmacology of zaleplon

扎来普隆一般药理实验研究

Objective : To research the synthesis technique of zaleplon .

目的：研究扎赖普隆的合成工艺。

Double blind and multi center clinical trial of Zaleplon capsule on insomnia

扎来普隆胶囊治疗失眠症的多中心临床研究

Determination of Content and Dissolution of Zaleplon Capsules by UV Spectrophotometry

扎来普隆胶囊溶出度和含量测定

AIM : To study the pharmacokinetics and relative bioavailability of zaleplon capsules .

目的：研究扎来普隆胶囊剂的人体相对生物利用度。

The dosage forms of Zaleplon mainly used on domestic and aboard clinical practice is tablet and capsule .

目前国内外临床上所用扎来普隆的剂型主要为片剂和胶囊剂等口服制剂。

Effect and reliability of zaleplon on treatment of insomnia : a randomized , double blind , controll study

扎来普隆治疗失眠症的疗效及安全性：随机双盲对照研究

The Second Phase Clinical Trials of the Second Category Novel Hypnotic , Zaleplon for the Treatment of Insomnia

二类新药扎来普隆治疗失眠的II期临床研究

CONCLUSION : The method is accurate , reliable and highly sensitive so it can be used in study of pharmacokinetics of zaleplon .

结论：本方法准确可靠，灵敏度高，重现性好，可用于扎莱普隆的药代动力学研究。

Zaleplon is an excitomotor of ω _1 receptor of Benzodiazepine which was widely used for the treatment of insomnia in clinic .

扎莱普隆是一种苯二氮卓ω1型受体的完全激动剂，临床主要用于治疗失眠症，具有起效快、不良反应少等特点。

OBJECTIVE To establish an HPLC-APCI-MS method for the study of pharmacokinetics and bioavailability of zaleplon by comparing the difference of zaleplon in electrospray ionization and atmospheric pressure chemical ionization mode .

目的：建立测定人血浆中扎来普隆的高效液相色谱-大气压化学离子化-质谱（HPLC-APCI-MS）分析方法，研究扎来普隆口腔崩解片的人体相对生物利用度。

Methods : The mice and rats with zaleplon treated were observed while climbing poles or being provoked or self-monitoring to decide the general reactions brought to cardiovascular or respiring systems .

方法：选取小鼠和大鼠分别观察给药后，对爬竿运动、自主活动、激怒反应以及对麻醉大鼠心血管系统和呼吸系统的影响。

The 24 cases of total patients were treated with zaleplon ( 5 ~ 10 ? mg / d ) and the others were treated with zolpidem ( 10mg / d ) for 2 weeks .

其中扎来普隆组24例（5～10mg/d），唑吡坦组24例（10mg/d），共治疗2周。